We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

117 hedge funds and large institutions have $132M invested in Ventyx Biosciences in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 37 increasing their positions, 37 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 37

7% less funds holding

Funds holding: 126117 (-9)

18.37% less ownership

Funds ownership: 99.58%81.21% (-18%)

25% less call options, than puts

Call options by funds: $670K | Put options by funds: $896K

28% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 29

59% less capital invested

Capital invested by funds: $324M → $132M (-$192M)

Holders
117
Holders Change
-9
Holders Change %
-7.14%
% of All Funds
1.69%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
21
Increased
37
Reduced
37
Closed
29
Calls
$670K
Puts
$896K
Net Calls
-$226K
Net Calls Change
-$431K
Name Holding Trade Value Shares
Change
Change in
Stake
DM
1
Deerfield Management
New York
$13.5M +$9.5M +2,287,570 +65%
Citadel Advisors
2
Citadel Advisors
Florida
$13.3M -$551K -132,498 -2%
Capital International Investors
3
Capital International Investors
California
$12.1M +$12M +2,893,497 +123%
BlackRock
4
BlackRock
New York
$11M +$4.26M +1,024,564 +27%
FCM
5
Farallon Capital Management
California
$7.32M
TCM
6
Tang Capital Management
California
$7.16M
Vanguard Group
7
Vanguard Group
Pennsylvania
$6.92M -$2.96M -711,230 -19%
OCA
8
Octagon Capital Advisors
New York
$5.52M +$3.7M +890,000 +59%
RG
9
Redmile Group
California
$5M
Goldman Sachs
10
Goldman Sachs
New York
$3.37M -$935K -224,957 -13%
VPC
11
Vestal Point Capital
New York
$3.04M +$5.46M +1,315,000 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$3.04M +$862K +207,542 +19%
OM
13
Opaleye Management
Massachusetts
$2.75M -$395K -95,000 -7%
State Street
14
State Street
Massachusetts
$2.72M +$1.04M +251,278 +27%
PHP
15
Parkman Healthcare Partners
Connecticut
$2.68M -$200K -48,077 -4%
SSA
16
Schonfeld Strategic Advisors
New York
$2.67M -$5.04M -1,213,059 -51%
SFM
17
Sphera Funds Management
Israel
$2.34M +$83.1K +20,000 +2%
JP Morgan Chase
18
JP Morgan Chase
New York
$2.28M +$140K +33,810 +4%
SCM
19
Sio Capital Management
New York
$1.8M +$1.67M +400,924 +106%
Morgan Stanley
20
Morgan Stanley
New York
$1.46M -$2.92M -703,561 -53%
Walleye Capital
21
Walleye Capital
New York
$1.18M +$810K +194,854 +62%
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$1.1M +$1.98M +475,726 New
Charles Schwab
23
Charles Schwab
California
$1.08M +$342K +82,320 +21%
WC
24
Wexford Capital
Florida
$1.04M +$1.74M +419,046 +1,397%
IC
25
Ikarian Capital
Texas
$1.02M -$270K -65,000 -13%

VTYX Hedge Fund Activity: Q2 2024 in Review

117 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q2 2024, worth a combined $132M — down 59% from $324M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of VTYX and 21 opened new positions — a net loss of 8 holders — while 37 trimmed existing stakes and 37 added.

The largest buyer was Capital International Investors, adding an estimated $12M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $14.9M sold.

  • 117 institutional investors held Ventyx Biosciences (VTYX) as of Q2 2024, down from 126 in Q1 2024.
  • Funds reported $132M of Ventyx Biosciences stock for Q2 2024, down 59% quarter-over-quarter.
  • 21 funds opened new Ventyx Biosciences positions in Q2 2024 and 29 closed out, a net change of -8 holders.
  • The largest Ventyx Biosciences buyer in Q2 2024 was Capital International Investors, an estimated $12M added.
  • The largest Ventyx Biosciences seller in Q2 2024 was Cormorant Asset Management, an estimated $14.9M sold.

Based on aggregated 13F filings for Q2 2024.